Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols

Pharmaceutical Research

Volumn 30, Issue 6, 2013, Pages 1608-1627

  Longest, P Worth ^a,b   Son, Yoen Ju ^b   Holbrook, Landon ^a   Hindle, Michael ^b  

^a Virginia Commonwealth University   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

dry power inhaler (DPI); excipient enhanced growth (EEG); non dimensional specific dissipation (NDSD); respiratory drug delivery; submicrometer inhaler

Indexed keywords

AEROSOL; AIRFLOW; AIRWAY DYNAMICS; ARTICLE; COMPUTATIONAL FLUID DYNAMICS; DISPERSION; DRY POWDER INHALER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL COMPUTING; MICROMETER AEROSOL; NON DIMENSIONAL SPECIFIC DISSIPATION; PARTICLE SIZE; PHYSICAL PARAMETERS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SUBMICROMETER AEROSOL; TURBULENT FLOW;

ADMINISTRATION, INHALATION; AEROSOLS; CAPSULES; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRY POWDER INHALERS; EQUIPMENT DESIGN; HYDRODYNAMICS; PARTICLE SIZE; POWDERS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84877736373     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1001-z     Document Type: Article

References (60)

1. Smith IJ, Bell J, Bowman N, Everard M, Stein S, Weers JG. Inhaler devices: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S25-37.
2. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293-304.
3. Islam N, Cleary MJ. Developing an efficient and reliable dry powder inhaler for pulmonary drug delivery - A review for multidisciplinary researchers. Med Eng Phys. 2012;34:409-27.
4. Byron PR. Drug delivery devices: issues in drug development. Proc Am Thorac Soc. 2004;1:321-8.
5. Borgstrom L, Olsson B, Thorsson L. Degree of throat deposition can explain the variability in lung deposition of inhaled drugs. J Aerosol Med. 2006;19:473-83.
6. Scheuch G, Bennett W, Borgstrom L, Clark A, Dalby R, Dolovich M. Deposition, imaging, and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S39-57.
7. Delvadia R, Hindle M, Longest PW, Byron PR. In vitro tests for aerosol deposition. II: IVIVCs for different dry powder inhalers in normal adults. J Aerosol Med Pulm Drug Deliv. 2012. doi: 10.1089/jamp.2012.0975.
8. Longest PW, Tian G, Walenga RL, Hindle M. Comparing MDI and DPI aerosol deposition using in vitro experiments and a new stochastic individual path (SIP) model of the conducting airways. Pharm Res. 2012;29:1670-88.
9. Chan H-K. Dry powder aerosol drug delivery - Opportunities for colloid and surface scientists. Colloids Surf A: Physicochem Eng Aspects. 2006;284-285:50-5.
10. Chan H-K. Dry powder aerosol delivery systems: current and future research directions. J Aerosol Med. 2006;19(1):21-7.
11. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Heterogeneous particle deaggregation and its implication for therapeutic aerosol performance. J Pharm Sci. 2010;99:3442-61.
12. Wong W, Fletcher DF, Traini D, Chan HK, Young PM. The use of computational approaches in inhaler development. Adv Drug Deliv Rev. 2012;64:312-22.
13. Voss AP, Finlay WH. Deagglomeration of dry powder pharmaceutical aerosols. Int J Pharm. 2002;248:39-40.
14. Longest PW, Hindle M. Quantitative analysis and design of a spray aerosol inhaler. Part 1: effects of dilution air inlets and flow paths. J Aerosol Med Pulm Drug Deliv. 2009;22:271-83.
15. Coates MS, Chan H-K, Fletcher DF, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 2: Air inlet size. J Pharm Sci. 2006;95:1382-92.
16. Coates MS, Fletcher DF, Chan H-K, Raper JA. Effect of design on the performance of a dry powder inhaler using computational fluid dynamics. Part 1: grid structure and mouthpiece length. J Pharm Sci. 2004;93:2863-76.
17. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of impaction effects for agglomerated systems. J Pharm Sci. 2011;100:2744-54.
18. Donovan MJ, Kim SH, Raman V, Smyth HD. Dry powder inhaler device influence on carrier particle performance. J Pharm Sci. 2011;101:1097-107.
19. Srichana T, Martin GP, Marriott C. Dry powder inhalers: the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci. 1998;7:73-80.
20. Louey MD, VanOort M, Hickey AJ. Standarized entrainment tubes for the evaluation of phamaceutical dry powder dispersion. J Aerosol Sci. 2006;37:1520-33.
21. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 1. Albuterol sulfate and disodium cromoglycate. J Pharm Sci. 2010;99:3398-414.
22. Xu Z, Mansour HM, Mulder T, McLean R, Langridge J, Hickey AJ. Dry powder aerosols generated by standardized entrainment tubes from drug blends with lactose monohydrate: 2. Ipratropium bromide monohydrate and fluticasone propionate. J Pharm Sci. 2010;99:3415-29.
23. Coates MS, Chan H-K, Fletcher DF, Raper JA. Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses. Pharm Res. 2005;22:1445-53.
24. Coates MS, Chan H-K, Fletcher DF, Chiou H. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhalation. Pharm Res. 2007;24:1450-6.
25. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers 1: evaluation and modelling of venturi effects for agglomerated systems. Pharm Res. 2010;27:1367-76.
26. Wong W, Fletcher DF, Traini D, Chan HK, Crapper J, Young PM. Particle aerosolisation and break-up in dry powder inhalers: evaluation and modelling of the influence of grid structures for agglomerated systems. J Pharm Sci. 2011;100:4710-21.
27. Adi S, Tong ZB, Chan HK, Yang RY, Yu AB. Impact angles as an alternative way to improve aerosolisation of powders for inhalation? Eur J Pharm Sci. 2010;41:320-7.
28. Weers JG, Bell J, Chan HK, Cipolla D, Dunbar C, Hickey AJ, et al. Pulmonary formulations: what remains to be done? J Aerosol Med Pulm Drug Deliv. 2010;23:S5-S23.
29. Yang JZ, Young AL, Chiang PC, Thurston A, Pretzer DK. Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies. J Pharm Sci. 2008;97:4869-78.
30. El-Gendy N, Gorman EM, Munson EJ, Berkland C. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009;98:2731-46.
31. Longest PW, Tian G, Li X, Son Y-J, Hindle M. Performance of combination drug and hygroscopic excipient submicrometer particles from a softmist inhaler in a characteristic model of the airways. Ann Biomed Eng. 2012;40:2596-610.
32. Longest PW, Hindle M. Condensational growth of combination drug-excipient submicrometer particles: comparison of CFD predictions with experimental results. Pharm Res. 2012;29:707-21.
33. Longest PW, Hindle M. Numerical model to characterize the size increase of combination drug and hygroscopic excipient nanoparticle aerosols. Aerosol Sci Technol. 2011;45:884-99.
34. Hindle M, Longest PW. Condensational growth of combination drug-excipient submicrometer particles for targeted high efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol. 2012;64:1254-63.
35. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the enhanced excipient growth application: effect of DPI design. Respiratory Drug Delivery. 2012;3:903-6.
36. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the enhanced excipient growth application: effect of spray drying conditions. Respir Drug Deliv. 2012;3:899-902.
37. Son Y-J, Longest PW, Hindle M. Aerosolization characteristics of dry powder inhaler formulations for the excipient enhanced growth (EEG) application: effect of spray drying process conditions on aerosol performance. Int J Pharm. 2013. doi: 10.1016/j.ijpharm.2013.01.003.
38. Raula J, Lahde A, Kauppinen EI. Aerosolization behavior of carrier-free L-leucine coated salbutamol sulphate powders. Int J Pharm. 2009;365:18-25.
39. Clark AR, Hollingworth AM. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers-Implications for in vitro testing. J Aerosol Med. 1993;6:99-110.
40. Ghalichi F, Deng X, Champlain AD, Douville Y, King M, Guidoin R. Low Reynolds number turbulence modeling of blood flow in arterial stenoses. Biorheology. 1998;35:281-94.
41. Wilcox DC. Turbulence modeling for CFD. 2nd ed. California: DCW Industries, Inc.; 1998.
42. Longest PW, Xi J. Condensational growth may contribute to the enhanced deposition of cigarette smoke particles in the upper respiratory tract. Aerosol Sci Technol. 2008;42:579-602.
43. Longest PW, Hindle M. Evaluation of the Respimat Soft Mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med. 2009;22:99-112.
44. Xi J, Longest PW, Martonen TB. Effects of the laryngeal jet on nano- and microparticle transport and deposition in an approximate model of the upper tracheobronchial airways. J Appl Physiol. 2008;104:1761-77.
45. Longest PW, Vinchurkar S. Validating CFD predictions of respiratory aerosol deposition: effects of upstream transition and turbulence. J Biomech. 2007;40:305-16.
46. Longest PW, Hindle M, Das Choudhuri S, Xi J. Comparison of ambient and spray aerosol deposition in a standard induction port and more realistic mouth-throat geometry. J Aerosol Sci. 2008;39:572-91.
47. Allen MD, Raabe OG. Slip correction measurements of spherical solid aerosol particles in an improved Millikan apparatus. Aerosol Sci Technol. 1985;4:269-86.
48. Longest PW, Kleinstreuer C, Buchanan JR. Efficient computation of micro-particle dynamics including wall effects. Comput Fluids. 2004;33:577-601.
49. Morsi SA, Alexander AJ. An investigation of particle trajectories in two-phase flow systems. J Fluid Mech. 1972;55:193-208.
50. Longest PW, Xi J. Effectiveness of direct Lagrangian tracking models for simulating nanoparticle deposition in the upper airways. Aerosol Sci Technol. 2007;41:380-97.
51. Gosman AD, Ioannides E. Aspects of computer simulation of liquid-fueled combustors. J Energy. 1981;7:482-90.
52. Crowe CT, Troutt TR, Chung JN. Numerical models for two-phase turbulent flows. Annu Rev Fluid Mech. 1996;28:11-43.
53. Matida EA, Nishino K, Torii K. Statistical simulation of particle deposition on the wall from turbulent dispersed pipe flow. Int J Heat Fluid Flow. 2000;21:389-402.
54. Longest PW, Hindle M, Das Choudhuri S, Byron PR. Numerical simulations of capillary aerosol generation: CFD model development and comparisons with experimental data. Aerosol Sci Technol. 2007;41:952-73.
55. Matida EA, Finlay WH, Grgic LB. Improved numerical simulation of aerosol deposition in an idealized mouth-throat. J Aerosol Sci. 2004;35:1-19.
56. Vinchurkar S, Longest PW. Evaluation of hexahedral, prismatic and hybrid mesh styles for simulating respiratory aerosol dynamics. Comput Fluids. 2008;37:317-31.
57. Longest PW, Vinchurkar S. Effects of mesh style and grid convergence on particle deposition in bifurcating airway models with comparisons to experimental data. Med Eng Phys. 2007;29:350-66.
58. Newman S. Respiratory drug delivery: Essential theory and practice. Richmond: RDD Online; 2009.
59. Finlay WH. The mechanics of inhaled pharmaceutical aerosols. San Diego: Academic; 2001.
60. Shur J, Lee SL, Adams W, Lionberger R, Tibbatts J, Price R. Effect of device design on the in vitro perfornace and comparability for capsule-based dry powder inhalers. AAPS J. 2012;14:667-76.